Ask The Board

1. What Is Your Biggest Concern Regarding The Biopharma Industry’s Reputation With The American People If We Don’t Have A COVID-19 Vaccine By The End Of This Year? 10/1/2020

   See the answer from Francois Nader, chairman of Acceleron Pharma.

2. What’s Your Perspective On The Rise Around Virtual Pitching To Investors, And What Will Be Its Impact On Annual Investor Meetings Like The Biotech Showcase And JPM In 2021? 10/1/2020

   See the answer from Dennis Purcell, a founder and senior advisor of Aisling Capital.

3. What — If Any — Silver Linings Have You Observed Taking Place At Your Company Resulting From The Chaos Caused By COVID-19? 10/1/2020

   See the answer from Joe Ferra, CFO of Syros Pharmaceuticals.

4. What Additional Protocols Have You Observed Being Implemented To Protect Biopharma Manufacturing Employees, And What Impact Do You Anticipate On The Bottom Line From These Added Costs? 9/1/2020

   See the answer from Jacks Lee, a global pharmaceutical executive with 25+ years of experiences in vaccines, biopharmaceuticals, and small molecule pharmaceuticals.

5. What Are Some Of The Best Business Practices That Didn’t Exist At Your Company Prior To COVID-19 That Will Likely Continue Long After The Pandemic Subsides? 9/1/2020

   See the answer from John Crowley, the Chairman & CEO of Amicus Therapeutics, a global biotech focused on developing medicines for people living with rare diseases.

6. Given The Success Of Virtual Investor Pitching, Do You Think Events Like JPM And BTS Will Remain Relevant? 9/1/2020

   See the answer from Martin Lehr, CEO and cofounder at Context Therapeutics, a clinical-stage biopharma dedicated to developing novel medicines for hormone receptor positive cancers.

7. What Advice Do You Have To Someone Beginning A Biopharma Job Search During These Unprecedented Times? 8/3/2020

   See the answer from Jason Urban, Ph.D., who heads up Alexion Pharmaceuticals’ Quality Risk Management function.

8. What Will Be The Three Greatest Learnings From The First Half Of 2020 That Will Change The Biopharma Industry Going Forward? 8/3/2020

   See the answer from Al Altomari, who is chairman and CEO of Agile Therapeutics and a member of the company’s board of directors.

9. What Has Been The Greatest Biopharma Business-Related Insight You Have Gained From Continued Operations During The First Half Of This Year? 8/3/2020

   See the answer from Pamela Contag, Ph.D., the CEO and president of BioEclipse Therapeutics, a clinical-stage, next generation immunotherapy company.

10. How Can A Cell Therapy Manufacturer Avoid The Impact Of Supply Chain Disruptions Via Single Use Systems (SUS), While Also Being Sustainable For The Environment? 7/1/2020

    See the answer from Raúl Diaz, who directs MSD Animal Health Large Molecules Biopharm Operations in Montes Claros, Brazil.